PIRS Pieris Pharmaceuticals Inc.

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin protein-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-expressing solid tumors. The company also develops PRS-344, a bispecific anticalin-antibody fusion protein targeting 4-1BB and PD-L1 for immuno-oncology diseases; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.

Pieris Pharmaceuticals Inc.

Peers

Recent Analyst Ratings for Pieris Pharmaceuticals Inc.

Pieris Pharmaceuticals Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Heron Elaine J

SEC Form 4 filed by Director Wessel Tadd S.

SEC Form 4 filed by Director Davis Todd C

SEC Form 4 filed by Chief Scientific Officer Martini Jeffrey S

SEC Form 4 filed by Chief Operating Officer Goin Kathleen

SEC Form 4 filed by CFO, Treasurer Korenberg Matthew E

SEC Form 4 filed by Director Jenkins George M

SEC Form 4 filed by President and CEO Kaupinen Wes

SEC Form 4 filed by Director Kiritsy Christopher P

See Explanation of Responses Bvf Partners L P/Il acquired 438,929 shares (SEC Form 4)

Pieris Pharmaceuticals Inc. Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Geraghty James A bought $1 worth of Series F Preferred Stock (1 units at $1.00) (SEC Form 4)

Large owner Adar1 Capital Management, Llc bought $92,326 worth of shares (6,000 units at $15.39) (SEC Form 4)

Pieris Pharmaceuticals Inc. SEC Filings

SEC Form 425 filed by Pieris Pharmaceuticals Inc.

Pieris Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Submission of Matters to a Vote of Security Holders, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

SEC Form 425 filed by Pieris Pharmaceuticals Inc.

Pieris Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

SEC Form 10-Q filed by Pieris Pharmaceuticals Inc.

SEC Form EFFECT filed by Pieris Pharmaceuticals Inc.

SEC Form 424B3 filed by Pieris Pharmaceuticals Inc.

SEC Form 425 filed by Pieris Pharmaceuticals Inc.

Amendment: SEC Form S-4/A filed by Pieris Pharmaceuticals Inc.